No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

TUESDAY, Jan. 21, 2025 (HealthDay News) -- The U.S. Department of Health and Human Services (HHS) is awarding the ...

Moderna (MRNA) stock gained in the premarket after the company received a tender to supply its COVID-19 vaccine in the EU, ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

As Moderna (NASDAQ: MRNA) looks to shore up its business in the wake of its declining coronavirus vaccine sales, it's natural ...

Moderna is developing an mRNA-based vaccine for norovirus, now in Phase 3 trials, with hopes of approval by 2026 to combat the highly contagious stomach virus.

MRNA intends to use the funds to support the development of its mRNA-based bird flu shot and expand clinical studies for ...

Under the agreement, 17 participating countries could order an updated version of the biotech company's mRNA Covid-19 vaccine for up to four years. The vaccine, marketed as Spikevax in Europe, was ...

"We remain focused on our three strategic priorities: driving sales growth, delivering up to 10 product approvals over the ...

Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.

The government wants Moderna to push forward with various bird flu vaccines as well as mRNA shots for other influenza strains ...